The Plateau Consultation: What Good Providers Assess at Stall Points

The scale stopped moving. You're still taking the medication. You're still eating less. But for the past four, six, maybe ten weeks, nothing has changed. This is the GLP-1 plateau, and it's one of the most common — and most mismanaged — points in treatment.

A plateau is not a failure of the medication or a failure of the patient. It's a signal that something in the treatment equation has shifted and needs to be identified. The quality of a prescribing provider shows most clearly at this moment: a good provider investigates before intervening. A mediocre provider reflexively increases the dose. A poor provider auto-refills the same prescription without asking questions.

This guide maps what a thorough plateau evaluation looks like, so you know what to expect — and what to ask for if your provider doesn't offer it.

First: Is It Actually a Plateau?

A true plateau is a period of 8–12 weeks at a stable, therapeutic dose with no measurable change in weight or body composition. That definition has several important components.

The 8–12 week threshold: Weight loss on GLP-1s is not linear. Periods of 3–6 weeks with no scale movement are normal — they're often periods of body composition change (losing fat while retaining or gaining lean mass, losing visceral fat that doesn't register on a scale as dramatically as subcutaneous fat, or redistributing fluid after dietary changes). Declaring a plateau at 4 weeks and immediately changing the plan is premature.

At a therapeutic dose: If you're still titrating, you haven't reached the dose where plateau assessment is meaningful. The starting doses (0.25 mg semaglutide, 2.5 mg tirzepatide) are acclimation doses, not therapeutic doses. A plateau evaluation is appropriate at 1.0 mg+ semaglutide or 5.0 mg+ tirzepatide, after you've been at that dose for at least 8 weeks.

No measurable change: "Measurable" includes body composition, not just scale weight. If your waist circumference is decreasing, or your body fat percentage is dropping, or your clothes are fitting differently — you're not in a true plateau. You're in a recomposition phase, which is actually a favorable outcome. Many patients experience weeks of stable scale weight while losing meaningful amounts of fat and gaining or preserving muscle, particularly if they're doing resistance training.

The Seven Assessment Areas

When a patient presents with a genuine plateau, a thorough provider evaluates these domains in sequence. The order matters — each builds on the last, and interventions at the top of the list should be addressed before resorting to those at the bottom.

1. Dietary Assessment: Are You Eating Enough Protein?

This is the single most common correctable factor in GLP-1 plateaus. Inadequate protein intake during GLP-1-mediated weight loss leads to accelerated lean mass loss. Less lean mass means lower resting metabolic rate. Lower metabolic rate means fewer calories burned at rest. The plateau isn't the medication failing — it's the body adapting to a lower energy expenditure driven by muscle loss.

What the provider should do: Review a 3-day food log (or dietary recall) with specific attention to total protein intake. The target is 1.0–1.2 grams of protein per kilogram of ideal body weight per day. Most GLP-1 patients are consuming 40–50 grams when they need 80–100+. If protein is low, fixing this single variable often restarts weight loss without any medication changes.

What to look for: Total daily calories under 1,000 is also a problem — severe caloric restriction triggers metabolic adaptation (reduced thyroid output, lower resting metabolic rate) that stalls weight loss. Eating too little is as problematic as eating too much.

2. Exercise Assessment: Are You Doing Resistance Training?

Resistance training is the primary intervention for preserving lean mass during GLP-1-mediated weight loss. Patients doing structured resistance training 2–3 times per week consistently lose more fat and retain more muscle than those who rely on the medication alone. At a plateau, the exercise question is: are you doing any? And if so, is it progressive (increasing challenge over time)?

What the provider should do: Ask about type, frequency, and progression of exercise. If the patient isn't doing resistance training, starting a basic program often breaks the plateau. If they are, the question is whether it's progressive or whether they've been doing the same routine for months (in which case the stimulus is no longer producing adaptation).

3. Medication Compliance Assessment

This is the assessment many patients find uncomfortable but good providers conduct without judgment. Are you taking every weekly dose? Are you taking it on schedule? Have you missed doses or stretched intervals? Is there any reason to suspect the medication's potency is compromised (storage issues, expired beyond-use date)?

What the provider should do: Review the medication log (if one exists) or ask directly. If the patient is consistently missing one injection per month, they're getting 75% of the expected medication exposure — enough to maintain weight but potentially not enough to continue losing. For compounded medications, the provider should also assess storage compliance and check the beyond-use date.

Red flag: If the patient has switched pharmacies or compounding sources and the plateau coincided with the switch, potency variation between compounders is a real concern. The FDA has documented significant potency inconsistencies in compounded semaglutide.

4. Sleep and Stress Assessment

Chronic sleep deprivation (consistently under 6 hours) and significant psychological stress both elevate cortisol levels, which promotes visceral fat retention and interferes with insulin sensitivity. These are modifiable factors that GLP-1 therapy does not override.

What the provider should do: Screen for sleep quality and duration (a simple "how many hours are you sleeping?" is a start). Screen for significant life stressors. If sleep or stress are clearly contributing, addressing these — even partially — can restart progress. This doesn't mean the plateau is "caused by stress" in a dismissive sense. It means cortisol is a real hormone with real metabolic effects that compete with GLP-1 activity.

5. Laboratory Assessment

A plateau lasting more than 12 weeks warrants lab work to rule out metabolic factors that can resist GLP-1 therapy.

Thyroid function (TSH, free T4): Hypothyroidism slows metabolic rate independently of GLP-1 effects. It's common, often subclinical, and easily treated. If TSH is elevated, thyroid replacement may break the plateau without any changes to GLP-1 therapy.

Fasting insulin and glucose: Significant insulin resistance can limit the metabolic response to GLP-1s. If fasting insulin is very high, the provider may consider adding metformin (which improves insulin sensitivity through a different pathway) as an adjunct.

Cortisol: Sustained elevated cortisol (from Cushing's syndrome, chronic stress, or corticosteroid use) resists weight loss. If clinical suspicion is high, a morning cortisol or 24-hour urinary free cortisol test is appropriate.

Vitamin D, B12, iron/ferritin: Deficiencies in these are common during caloric restriction and can cause fatigue, reduced exercise capacity, and metabolic slowing that contributes to plateaus.

6. Dose Optimization

If assessments 1–5 have been addressed and the plateau persists, dose increase is the appropriate next step. This is where many providers start — but it should be step 6, not step 1.

What the provider should do: If the patient is on a sub-maximal dose, titrate up by one dose step and re-evaluate at 8 weeks. If the patient is already at the maximum dose and all modifiable factors have been optimized, the medication has likely achieved its maximal effect at this dose in this patient.

The ceiling question: Every medication has a ceiling of effect in every individual. Not every patient will lose the same amount of weight on the same dose of the same medication. The average weight loss in clinical trials is an average — half of patients lose more, half lose less. Reaching a ceiling is not a medication failure; it's the expected endpoint for that individual at that dose.

7. Molecule Switch or Combination Therapy

If all six previous assessments have been optimized and the plateau persists at the maximum tolerated dose, the final clinical options are switching molecules (see our Sema-to-Tirz Crossover Protocol) or adding adjunctive therapy.

Adjunctive options include: Metformin (addresses insulin resistance), phentermine (short-term appetite suppression through a different mechanism), topiramate (appetite suppression + some metabolic effects), and naltrexone-bupropion (Contrave). These are prescription decisions that require individual risk-benefit assessment. Some compounding pharmacies and telehealth platforms offer combination formulations.

Paid link

Considering a new provider for your plateau evaluation?

Embody — Provider messaging for dosing guidance

Injectable semaglutide from $69–99 first month (ongoing ~$299/mo). Discuss plateau management with your prescriber.

See Embody →

Compounded semaglutide — not FDA-approved. Injectable only.

Wellorithm — Oral tablets if switching format helps

Compounded semaglutide tablets $147/mo, tirzepatide $249/mo. Different absorption profile may suit some plateau patients.

See Wellorithm →

Compounded tablets — not FDA-approved.

What a Bad Plateau Response Looks Like

For comparison, here are the plateau responses that indicate your provider is not managing the situation well.

"Just keep going, the weight will come off eventually." This dismisses the plateau without investigation. It may resolve on its own, but 12 weeks without change deserves at least a dietary and lab assessment.

Immediately doubling the dose. Jumping two titration steps without evaluating modifiable factors is aggressive and often produces severe side effects without proportional benefit.

Suggesting you "try harder" with diet. If the provider hasn't reviewed a food log or set specific protein targets, this is vague advice rather than clinical guidance.

Auto-refilling without a check-in. A plateau is a clinical event. If your provider doesn't recognize it as one — if the refill process is so automated that nobody notices you've stopped losing weight — the monitoring is inadequate.

A provider who works through the seven-step assessment above may or may not change your medication. The value isn't in the conclusion — it's in the process. A thorough evaluation often reveals correctable factors that restart progress without any medication changes at all.

Paid link

GobyMeds: Flexible enough to pause and switch if needed

No subscription, no auto-renew. If your plateau evaluation leads to a medication change, there's nothing to cancel. Semaglutide from $99/mo.

See GobyMeds Plans →

Compounded medication — not FDA-approved. Dispensed by licensed 503A pharmacies.